Blade, Thanks, I'll check them out. Btw, here's an interesting one called Anavex (AVXL), though it's already had a sizable move. Some summary/backround posts -
>>> One other stock I've been following is Anavex (AVXL), a biotech with an early stage Alzheimer's drug. I started following them loosely in the Summer when it was under $2, and today it just blasted thru $14. A while back Neuro/Dr. Tracy posted that he knows the CEO pretty well (Dr. Missling), and pharma interest in the drug's mechanism is increasing. Their drug has shown early indications of a synergistic effect with Aricept (which is now generic), so there could be the potential for considerable interest from big pharma for the combo drug. The current treatments for Alzheimer's are truly pathetic - the ACHase inhibitors like Aricept, and the NMDA receptor inhibitor Namenda, which you might remember from the Cortex days. These have virtually zero efficacy, but have still generated some big revenues over the years since they are all that's available.
Anavex recently reverse split as part of an uplisting onto the Nasdaq, and announced a favorable financing last week, with Phase 2a data due soon. The chart since last Spring is absolutely stunning, and with the stock now trading on Nasdaq, institutional money is coming in. Huge volume today, and the market cap is approaching 1/2 Billion $, so the stock is entering the momo phase and some caution is warranted, but a fun one to watch. <<<
And -
>>> One thing to keep in mind with these Anavex studies is that they are 'open label', ie they aren't blinded. So the results are already known to the investigators. The fact that Missling could have done such a favorable financing deal indicates that the results are likely reasonably good. That removes a lot of the binary risk. On the other hand, unblinded/open label data is of much less statistical value. But these trials are not intended for that, the primary endpoint is to determine the MTD/Max Tolerated Dose, something that is normally done in Phase 1. Since the safety aspect doesn't look like it's going to be a factor, the secondary endpoints are of primary interest - indications of efficacy and synergy with Aricept. The severe lack of treatments for Alzheimer's is what has propelled the interest in Avanex, to a market cap over $300 mil for a company with almost no cash. The fact that Missling attracted such a good financing arrangement indicates that the open label clinical trial results are promising, since the financing entity would have had access to the results before signing the deal. <<<
Market Data 
Markets 
AI
